Oxidative stress, mitochondrial dysfunction, and ferroptosis in the placenta of gestational diabetes mellitus Authors: Xuan Zhou, Huiting Zhang, Lijie Wei, Zizhuo Wang, Shenglan Zhu, Jun Yu, Shaoshuai Wang, Wencheng Ding, Ling Feng, Jianli Wu Published: 2025 ABSTRACT AbstractGestational diabetes mellitus (GDM) has become a significant concern in the domain of women’s health. The pathophysiology of GDM is complicated and not entirely understood. As a functional interface of the maternal and fetal metabolisms, it is evident that the placenta exerts an effect on the development of GDM. The placenta not only involves itself in insulin resistance via the production of hormones, but also serves as an organ abundant in mitochondria and exhibits intense metabolic activities, rendering it particularly vulnerable to the adverse effects of oxidative stress. In the high-glucose environment, excessive oxidative damage leads to mitochondrial dysfunction and further induces ferroptosis by facilitating lipid peroxidation. The objective of this review is to predominantly assess recent research, published within the last five years, that investigates the roles of placental oxidative stress, mitochondrial dysfunction, and ferroptosis as pathological mechanisms influencing the development of GDM. Understanding these pathological changes may help to better explore novel therapeutic strategies for GDM.Keywords: Gestational diabetes mellitus, Placenta, Oxidative stress, Mitochondrial dysfunction, Ferroptosis Introduction Gestational diabetes mellitus (GDM) is identified as hyperglycaemia initially detected during pregnancy. It has been reported that GDM remains one of the most common pregnancy complications, with an incidence of around 14% in maternity in a global context [1]. Becoming a major health problem, GDM is related to ranges of perinatal complications affecting both mother and offspring [2, 3]. Several meta-analyses have shown that GDM women had increased odds of caesarean section, preterm delivery, and macrosomia in their pregnancy outcomes and a nearly tenfold higher risk of progressing to type 2 diabetes mellitus in the future [4, 5]. Therefore, an improved understanding of the pathophysiological mechanisms of GDM is essential to reduce adverse outcomes of pregnancy and prevent possible long-term complications. The placenta serves as the principal regulator of pregnancy. In healthy pregnant women, due to various hormones like prolactin, estrogen, and progesterone secreted by the placenta [6], the extent of insulin resistance gradually increases as pregnancy progresses, for adaptation to the needs of the fetus for glucose and other nutrients [7]. In the meantime, insulin secretion in maternity is enhanced to maintain the stability of blood glucose levels. Nevertheless, there are excessive insulin resistance and secretory dysfunction of pancreatic beta-cells in GDM patients [8]. Because the placenta possesses the ability to sense and adapt to variations in the gestational environment, malfunction of the placenta has been apparently associated with complications in pregnancy [9]. Mitochondria within the placenta are integral to the sustenance of pregnancy [10]. The majority of cellular energy is generated by mitochondria through the tricarboxylic acid cycle and oxidative phosphorylation, processes that are concomitant with the production of reactive oxygen species (ROS) [11]. In GDM, the placenta is susceptible to a hyperglycemic environment, accompanied by changes of heightened inflammation and oxidative stress, dyslipidemia, and altered hormone levels. These alterations have the potential to disrupt placental development and function, thereby negatively impacting the health of both the mother and the fetus [12]. Studies have shown that the unfavorable intrauterine environment associated with GDM might modify the programming of fetal metabolic functions [13]. Recently, there have been a growing number of researches showing that placental oxidative stress, mitochondrial dysfunction, and ferroptosis of trophoblastic cells are involved in insulin resistance and metabolic disorders of GDM [14]. The heightened oxidative stress observed in the placenta during GDM can induce a range of pathophysiological alterations, thereby affecting the health of both the mother and the fetus. There exists a significant association between oxidative stress and mitochondrial dysfunction, as impaired mitochondria serve as a primary source of ROS. Mitochondrial dysfunction frequently results in diminished oxidative capacity and an overproduction of ROS, which can subsequently induce ferroptosis by facilitating lipid peroxidation. Understanding the interrelationship among oxidative stress, mitochondrial dysfunction, and ferroptosis in the placenta of GDM is essential for developing targeted therapeutic interventions. Here, we summarized the current understanding of the above pathological changes of the placenta in the pathogenesis of GDM with the view of helping to develop a novel target for intervention. We also discuss some potential antioxidant treatment strategies for GDM. Placental oxidative stress in GDM During pregnancy, ROS are mainly originated from placenta [15, 16]. The placenta is an organ abundant in mitochondria and exhibits enhanced mitochondrial activities, attributable to its intense metabolic processes [17, 18]. Oxidative phosphorylation is a critical biochemical process occurring within the inner membrane of mitochondria, facilitated by the electron transport chain [19]. ROS are produced as by-products of oxidative phosphorylation. Moderate ROS facilitate the adaptation of cells and tissues to fluctuating environmental conditions [10]. Excessive ROS adversely impacts the integrity of cellular functions, enzymes, and lipid membranes. Proteomics analyses have demonstrated that the placenta in GDM exhibited changes associated with oxidative stress [20]. The elevated levels of oxidative stress in GDM placenta originated from an imbalance between the production of ROS and the antioxidant defence system [21]. Elevated glucose levels contribute to enhanced free radical production through the activation of various metabolic pathways [22]. Additionally, glucose directly stimulates ROS production in placental mitochondria [23]. In GDM maternity, if there is no corresponding enhancement in antioxidative activity, oxidative stress is likely to ensue (Fig. 1). Placental oxidative stress in GDM. In GDM patients, elevated maternal glucose levels stimulate excessive production of ROS in placental mitochondria, while the antioxidative activities of the placenta are not sufficient, thereby inducing the occurrence of oxidative stress and resulting in many oxidative products. 8-isoPGF2α: 8-iso-prostaglandin F2α; 8-OHdG: 8-hydroxy-2′-deoxyguanosine; AGEs: advanced glycation end-products; CAT: catalase; GDM: gestational diabetes mellitus; GPx: glutathione peroxidase; GST: glutathione-S-transferase; LPO: lipid peroxidation; MDA: malondialdehyde; ROS: reactive oxygen species; SOD: superoxide dismutase; XO: xanthine oxidase. Created in BioRender.com Levels of oxidative stress in GDM Oxidative stress can be quantified through three primary methodologies: direct quantification of ROS levels; indirect evaluation of ROS-induced damage to proteins, lipids, and DNA, as well as the activity of ROS-generating enzymes; assessment of the antioxidant defense status [24]. In normal pregnancies, biomarkers of oxidative stress, including malondialdehyde (MDA), 8-hydroxy-2′-deoxyguanosine (8-OHdG), and thiobarbituric acid reactive substances (TBARS), are observed at elevated levels, reflecting a necessary augmentation in oxidative load to facilitate physiological processes [25]. MDA primarily originates from the peroxidation of polyunsaturated fatty acids (PUFAs) [26]. 4-Hydroxynonenal (4-HNE), another byproduct of lipid peroxidation, can influence lipogenesis and the uptake of fatty acids into the placenta [27]. In the context of GDM, evidence indicates a further marked rise in circulation markers such as MDA, 8-iso-prostaglandin F2α (8-isoPGF2α), and advanced glycation end-products (AGEs) relative to normal pregnancies. Besides, placentas from GDM pregnancies exhibited elevated levels of the oxidized DNA product, 8-OHdG [28], and significantly heightened levels of lipid peroxidation (LPO) and 4-HNE [29, 30]. Increased levels of active xanthine oxidase (XO) were detected in maternal plasma, placenta, and umbilical cord blood in cases of GDM, probably because inflammatory cytokines could enhance the production and activity of XO [24]. These findings imply a potential contributory role of oxidative stress in the pathogenesis of GDM [25]. Comprehending the interplay between placental oxidative stress and GDM is essential for effectively managing the complications associated with this condition. The influence of oxidative stress on GDM placenta In the human placenta during the first trimester, a low oxygen environment is essential for proper development. This physiologically hypoxic condition facilitates trophoblast proliferation, angiogenesis, and provides protection against damage from reactive oxygen species [31]. Around 10–12 weeks into gestation, maternal blood begins to flow into the intervillous space, sharply raising glucose and oxygen levels. This sudden increase could cause massive oxidative stress [32]. Oxidative stress during pregnancy presents a dual impact on embryonic and placental development [33]. On one hand, oxidative stress plays a significant role in the processes of implantation, placentation, and immunomodulation. On the other hand, excessive oxidative stress could disrupt appropriate development of the placenta, thus leading to adverse pregnancy outcomes. Oxidative stress and inflammation could promote pathological angiogenesis, causing structural abnormalities in the placental vasculature, which in turn lead to malperfusion and impaired fetal growth [34]. It explains why GDM exhibited placental vascular lesions, such as fibrinoid necrosis, fetal thrombotic vasculopathy, and increased fibrinoid deposition in intervillous spaces [35]. Villous hypervascularization, characterized by an increased number of branches per capillary within terminal villi, is also observed in placentas affected by GDM [31]. Studies suggested that oxidative stress could disrupt the characteristics of extravillous trophoblasts (EVTs), potentially elucidating the association between oxidative stress and pregnancy-related disorders [36]. In addition, a research revealed that GDM placentas exhibited increased size, edematous, and immature villus [37]. The abnormality of placental weight and volume is linked to hyperglycemia and is reported to result from the proliferation of villous tissue and the expansion of the intervillous space [31]. Villous edema and immaturity, marked by fewer and smaller terminal villi and more immature intermediate villi, would result in the barrier to maternal-fetal exchange efficiency and reduced placental function. Another study found that the expression of thioredoxin-interacting protein (TXNIP) was upregulated in the placentas of women with GDM. This increase can lead to oxidative stress and is associated with impaired placental function in GDM [38]. The capacity of antioxidant defense in GDM placenta Placenta possesses a variety of antioxidant defense mechanisms to effectively handle the increasing oxidative stress induced by ROS throughout pregnancy [19]. Superoxide dismutase (SOD) is a crucial antioxidant enzyme that plays a critical role in detoxifying superoxide radicals and the first line of intracellular defense against ROS [39]. There are two SOD isoforms within the placenta: copper-zinc-containing SOD-1 (Cu/Zn-SOD), which is localized in the villous stroma, and manganese-containing SOD-2 (MnSOD), which is found in the villous endothelium [40]. Glutathione peroxidase (GPx) is a selenoprotein involved in reducing lipid hydroperoxides, and GPx1-4 have been identified in the human placenta [41]. Catalase (CAT) and GPx could catalyze the decomposition of hydrogen peroxide to H2O and O2, also pivotal in cellular defense against oxidative damage in GDM [42]. Glutathione-S-transferase (GST) plays a role in the detoxification of products of oxidative stress [43] and serves as a biomarker for evaluating antioxidant activity. Studies have demonstrated a reduction in GST activity in GDM placenta [20]. A previous work has suggested that the variation in the levels of antioxidant enzymes, such as SOD, GPx, and CAT, between patients with GDM and their healthy counterparts did not reach statistical significance [29]. Other findings demonstrated elevated concentrations of SOD-1 and CAT in the GDM placenta [44]. This is probably related to the adaptation mechanism against enhanced oxidative stress, thereby protecting the fetus from the detrimental effects of oxidative excess [42, 45], whereas data from several studies have demonstrated a reduction in antioxidants, specifically SOD and CAT in the placenta of GDM [33, 46]. Animal experiments confirmed that in the high-fat diet (HFD) induced GDM mouse placenta, the activity of GPx was noticeably reduced [29], likely as a result of being overwhelmed by the elevated levels of ROS [43]. Pregnant women with overweight or obese are at an increased risk of developing GDM [47]. The expression of the antioxidant enzyme SOD2 was reported to be inversely correlated with maternal body mass index (BMI), suggesting a potential compromise in antioxidant defenses as BMI increases, which may contribute to an elevated production of ROS in the placenta [48]. Other research found reduced SOD3 expression in GDM placental trophoblastic cells [20]. The alterations in antioxidant enzyme activities are dependent upon the developmental stage of the placenta and can be induced in response to the progressively increasing levels of ROS in GDM pregnancies [17]. Variations in GDM diagnostic criteria and sample collection timing also might explain differences in antioxidant enzyme levels and activities. Signaling pathways associated with oxidative stress in GDM An excess of ROS can enhance inflammatory responses through the activation of various kinases and transcription factors, including the nuclear factor-kappa B (NF-κB) [18]. NF-κB is an intracellular molecule whose activation induces the production of ROS through the activity of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase [23]. NADPH oxidase is a kind of pro-oxidative enzyme, known as a main physiological source of ROS in placenta [40]. NF-κB inflammatory pathway and the janus kinase pathway (JAK)/signal transducers and activators of transcription 3 (STAT3) pathway have been associated with the development of GDM [22]. Previous study found that ROS could lead to the downregulation of glucose transporter 4 (GLUT4), which in turn contributes to insulin resistance and a reduction in glucose uptake [49]. In hyperglycemia in pregnancy, increased expression of GLUT1 and decreased expression of GLUT3 may impact the transport function of the placenta [50]. The AMP-activated protein kinase α (AMPKα)/p38 mitogen-activated protein kinase (p38 MAPK) signaling pathway plays a crucial role in modulating the expression of the placental glucose transporter GLUT1, which is influenced by oxidative stress resulting from hyperglycemia in GDM [50]. The NRF2 signaling pathway, essential for maintaining vascular redox homeostasis, is found dysregulated in GDM, thereby affecting placental angiogenesis [51]. Diminished expression of NRF2 in the placenta is correlated with adverse pregnancy outcomes [52]. The activation of NRF2 through dietary sulforaphane (SFN) intake during pregnancies with glucose intolerance could mitigate oxidative damage [52]. NRF2 facilitates the transcription of a range of antioxidant genes, including heme oxygenase-1 (HO-1) and SOD [51, 52]. The overexpression of HO-1 induced by the activation of NRF2 plays a crucial role in the elimination of ROS, thereby safeguarding the placenta against oxidative stress [51]. Besides, the upregulation of HO enzymes enhances insulin secretion from pancreatic beta cells and mitigates hyperglycemia. Studies have found that elevated HO-1 activity in serum is associated with a reduced risk of GDM [53]. Elevated levels of ROS in pregnancy complications can interfere with the calcium signaling pathway, resulting in an increased concentration of cytosolic Ca2+ and the initiation of apoptotic processes [9]. Exposure to oxidative stress can disrupt Ca2+ balance, prompting the activation of the mitochondrial permeability transition pore. This event initiates the mitochondrial permeability transition, a critical step in the cell death process (Fig. 2). Signaling pathways related to oxidative stress in GDM. The increased expression of GLUT1 and decreased expressions of GLUT3 and GLUT4 on cell membrane contribute to a reduction in glucose uptake and the extracellular high-glucose environment, which cause diminished expression of NRF2 and elevated ROS levels. ROS could interfere with calcium signaling pathway and activate NF-κB pathway as well as JAK/STAT3 pathway, further prompting oxidative stress and inflammatory response. AMPKα: AMP-activated protein kinase α; GLUT: glucose transporter; JAK: janus kinase; NF-κB: nuclear factor-kappa B; NRF2: nuclear factor erythroid 2-related factor 2; P38 MAPK: P38 mitogen-activated protein kinase; ROS: reactive oxygen species; STAT3: signal transducers and activators of transcription 3; ‌Tyk2: tyrosine kinase 2. Created in BioRender.com Mitochondrial dysfunction of placental trophoblastic cells in GDM Mitochondria play a crucial role in supplying energy necessary for sustaining cellular viability. The mitochondria in syncytiotrophoblasts (STBs) are responsible for placental steroid hormone production, especially progesterone [10]. Given that trophoblast mitochondria are pivotal for physiological activities, their dysfunction can significantly impair the functions of trophoblast. Dysfunction in mitochondrial processes can result in adenosine triphosphate (ATP) depletion and an overproduction of ROS, potentially causing mitochondrial damage and altering the redox balance of the entire cell [39]. Mechanisms of placental mitochondrial dysfunction in GDM Resistin has been associated with insulin resistance in normal pregnancy, but its elevated expression in GDM may damage placental mitochondrial biogenesis and function [54]. Evidence shows that the protein levels of the peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) and mitochondrial transcription factor A (TFAM) were diminished in GDM placentas, indicating a substantial impact on the regulation of mitochondrial biogenesis and energy metabolism [28, 55]. Previous studies have revealed a significant reduction in the expression of disulfide-bond A oxidoreductase-like protein (DsbA-L), also called GST kappa (GST-κ), in GDM [55, 56]. DsbA-L, a protein originating from the mitochondrial matrix, plays a critical role in the folding of proteins necessary for mitochondrial DNA (mtDNA) replication [57]. The suppression of DsbA-L leads to the extensive release of mtDNA, which activates the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway and further promotes insulin resistance [58]. The maternal diabetic status impacts the pathway of placental mitochondrial biogenesis [59] and impairs lipid metabolism and hormone secretion [60]. Mitochondria play a key role in lipid transport and are vital for fatty acid metabolism. Simultaneously, fatty acids play a regulatory role in mitochondrial biogenesis through a feedback mechanism. The lipotoxicity may exacerbate mitochondrial dysfunction and promote the production of ROS [61], which can enhance inflammation, thereby impairing angiogenesis and adversely affecting placental structure and function [62]. For instance, increased concentrations of lysophosphatidylcholine in the umbilical cord blood of patients with GDM were found to disrupt mitochondrial homeostasis in a dose-dependent manner, resulting in trophoblast dysfunction [61]. Alterations of functions and structure of placental mitochondria in GDM Mitochondrial dynamic changes, along with mitochondrial biogenesis and mitophagy, contribute to maintaining a healthy population of mitochondria. The maintenance of placental mitochondrial homeostasis plays a crucial role in ensuring a healthy pregnancy [63]. GDM particularly affects mitochondrial dynamics and energy production [64]. GDM could lead to diminished activity of mitochondrial enzymes, such as ATP-synthase, within placental tissues, thereby adversely affecting energy production. Mitochondrial dysfunction also involves disturbances in mitochondrial biogenesis and mitophagy, essential processes for maintaining cellular energy balance and function in the placenta [64]. Mitochondrial dysfunction in GDM is linked with altered expression of mitochondrial fusion proteins such as mitofusin 1 (MFN1), mitofusin 2 (MFN2), and optic atrophy 1 (OPA1), which are crucial for maintaining mitochondrial integrity and function [65]. The most metabolically active proliferating cell layer in the placenta is the cytotrophoblast. Mitochondria from GDM placental cytotrophoblast displayed elevated OPA1 and reduced dynamin-related protein 1 (DRP1) levels, suggesting an active fusion process [63]. Furthermore, relative to the normal pregnant women, the mitochondrial morphology of placental trophoblastic cells in GDM was swollen, indicated by the smaller specific surface [55]. It has been suggested that mitochondrial fusion might act as a protective strategy to prevent apoptosis and is necessary for the progression of human pregnancy. Research indicates a reduction in placental ceramide that triggers mitochondrial fission in GDM. Hyperinsulinaemia in GDM may aid the placenta in adapting to high oxidative phosphorylation demands through the stimulation of mitochondrial fusion [66]. It is vital for the placenta to possess regular expression and activity of mitochondrial electron transfer complexes I–IV and ATP-synthase. In GDM placentas, there is a significant reduction in the expression of electron transport chain complexes [28]. Alterations in the electron transport chain and ATP-synthase activity probably cause the decreased ATP production in the placenta of GDM patients [63]. In addition, elevated ROS lead to higher lipid peroxidation, which in turn reduces ATP generation and constrains mitochondrial respiration in GDM [28] (Fig. 3). Mitochondrial dysfunction in GDM placenta. In normal pregnancies, mitochondrial dynamics (fusion and fission), biogenesis, and mitophagy collectively maintain mitochondrial homeostasis. ATP is primarily generated by mitochondria through oxidative phosphorylation and the tricarboxylic acid cycle; ROS are concomitantly produced as by-products of oxidative phosphorylation. In the context of GDM, hyperglycemia leads to mitochondrial dysfunction, manifested as a significant decrease in the expression of ETC complexes, causing ATP depletion and excessive production of ROS, as well as lipid peroxidation. Elevated OPA1 expression and reduced DRP1 level indicate the active fusion process. Downregulated levels of DsbA-L, PGC-1α, and TFAM lead to the massive release of mtDNA, which activates the cGAS-STING pathway, further triggering inflammation and insulin resistance. ATP: adenosine triphosphate; cGAS: cyclic GMP-AMP synthase; DRP1: dynamin-related protein 1; DsbA-L: disulfide-bond A oxidoreductase-like protein; ETC: electron transport chain; GDM: gestational diabetes mellitus; GLUT: glucose transporter; IRF3: interferon regulatory factor 3; MFN1/2: mitofusin 1/2; mtDNA: mitochondrial DNA; OPA1: optic atrophy 1; OXPHOS: oxidative phosphorylation; PGC-1α: peroxisome proliferator-activated receptor-γ coactivator-1α; ROS: reactive oxygen species; STING: stimulator of interferon genes; TCA cycle: tricarboxylic acid cycle; TFAM: mitochondrial transcription factor A. Created in BioRender.com The effects of placental mitochondrial dysfunction on the offspring in GDM The mitochondrial genome exhibits heightened susceptibility to damage from ROS, and oxidative stress might change mtDNA, leading to impaired mitochondrial biogenesis and function in the fetus and the subsequent increased production of ROS [63]. GDM is correlated with a reduction in mitochondrial fatty acid oxidation, an elevation in placental triglyceride content, and a diminished proportion of saturated fatty acids [12]. Inflammation induced by lipotoxicity in the placenta may significantly affect fetal growth and development [67]. GDM affects mitochondrial function via elevating ROS levels and oxidative stress, while concurrently reducing trophoblast respiration. This effect is particularly pronounced in male fetuses, indicating a sexually dimorphic impact on placental development [46]. Evidence suggests that alterations in the GDM placenta vary by fetal sex, with male fetuses potentially more susceptible to hyperglycemia [20]. Placental STBs derived from the female fetuses exhibit a more adaptive response to energy changes compared to those from male fetuses [68]. Elevated levels of androgens have been linked to mitochondrial dysfunction in GDM. Research demonstrated that exposure to testosterone led to an increase in the production of ROS by trophoblast mitochondria. Additionally, prolonged exposure to testosterone resulted in a boost in the quantity of mitochondria within trophoblasts [69]. Elevated testosterone levels were also found to reduce trophoblast respiration, thereby inducing mitochondrial dysfunction [46]. Mitochondrial impairment further results in elevated production of ROS, exacerbating oxidative stress in the placental environment. A study demonstrated that metformin influenced the mitochondrial function of STBs in a sexually dimorphic manner [68]. Prolonged exposure to elevated lipid levels in conjunction with high glucose concentrations inevitably induced apoptosis in trophoblasts. Notably, the respiratory capacity of trophoblasts subjected to the exposure is significantly reduced, despite an observed increase in mitochondrial abundance [62]. In addition, compared to cytotrophoblasts (CTBs), STBs exhibit a reduced capacity for antioxidant activity, diminished mitochondrial respiration, and altered metabolic processes. These characteristics position them as the most sensitive region of the placenta in responding to fluctuations in oxygen levels [10]. Therapeutic interventions aimed at mitochondria may enhance the respiratory function of trophoblasts [46]. In sum, abnormalities in mitochondrial function and content within the placenta are linked to compromised placental energetics and elevated oxidative stress, ultimately contributing to adverse pregnancy outcomes. Ferroptosis of placental trophoblastic cells in GDM Ferroptosis, distinguished by intracellular increased ROS production, along with heightened fatty acid oxidation, impairs trophoblast invasion [70]. The interaction between oxidative stress and ferroptosis is evident as oxidative stress leads to lipid peroxidation, a key process in ferroptosis, and this pathway is influenced by mitochondrial dysfunction and iron metabolism. Previous in vivo studies revealed that the high-fat, high-sugar diet influenced the capacity for placental iron transfer, resulted in the dysregulation of genes associated with ferroptosis, and increased iron-dependent oxidative damage [71]. Abnormal iron metabolism in GDM Of key importance is that pregnant women exhibiting elevated iron levels are at an increased risk of developing GDM [72]. The administration of supplemental iron at doses of 60 mg/day or higher during mid-pregnancy was correlated with an elevated risk of GDM. This association was particularly significant among pregnant women exhibiting medium plasma ferritin concentrations (29.6–89.9 ng/mL) [73]. Free iron exhibits high reactivity, which can result in the generation of free radicals, subsequently leading to enhanced lipid peroxidation and mitochondrial dysfunction. Excessive iron levels contribute to the development of GDM by promoting oxidative stress [74]. The cytological alterations observed in ferroptosis are predominantly characterized by mitochondrial abnormalities [70]. Ferroptotic cells frequently demonstrate mitochondrial swelling, a diminished number of cristae, reduction of mitochondrial membrane potential, and enhanced mitochondrial membrane permeability, collectively indicative of mitochondrial dysfunction [39]. A study investigating lactoferrin revealed a correlation between decreased lactoferrin levels, diminished expressions of regulators of ferroptosis like glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11), and elevated blood glucose levels in GDM patients, thereby providing evidence for the involvement of ferroptosis in the pathophysiology of GDM [75]. Clinical studies have demonstrated that maternal serum ferritin (SF) levels are independently and positively correlated with the risk of GDM during both early and late stages of pregnancy [76]. Elevated ferritin levels have been associated with an increased risk of GDM, since iron overload may contribute to insulin resistance and β-cell dysfunction by exacerbating oxidative stress and inflammatory responses [77]. There is ongoing debate concerning the administration of prophylactic iron supplementation in populations deemed to be at low risk [74]. Glutathione (GSH), a common cellular antioxidant, is predominantly synthesized in the cytoplasm and subsequently transported to the mitochondria. In circumstances characterized by elevated levels of ROS, the functionality of mitochondrial enzymes is compromised, leading to a reduction in GSH levels [39]. The reduced GSH levels, disrupted iron transport, and elevated lipid peroxidation observed in hyperglycemic cell models indicate the occurrence of ferroptosis [72]. The substantial decrease in placental iron uptake under hyperglycemic conditions may represent a physiological mechanism designed to safeguard the placenta and fetus from potentially detrimental levels of iron [72]. Lipid peroxidation in placenta of GDM Recently, the significant role of lipid ROS in the process of ferroptosis has been elucidated [78]. Alterations in the essential energy substrates, such as glucose and lipids, may enhance the accumulation of ROS and initiate the peroxidation of PUFAs, thereby increasing the susceptibility to ferroptosis [79]. Lipid peroxidation is a characteristic feature of ferroptosis, leading to the direct disruption of cellular membranes and consequently inducing ferroptotic cell death [78]. The placenta plays a vital role in nutrient transport, a function that can be adversely affected in mothers with metabolic abnormalities. In the context of GDM, alterations in gene expression associated with lipid metabolism are more pronounced than those related to glucose metabolism [20]. Compelling evidence indicates the presence of dyslipidemia and abnormalities in the insulin signaling pathway in pregnant women with GDM [6, 47]. The elevated lipid levels in maternal circulation are translocated to the plasma membrane of placental microvilli, thereby impacting lipid metabolism and enhancing lipid transport to the placenta [67]. Modifications in lipid metabolism of GDM maternity, as indicated by altered triglyceride and cholesterol levels [80], may intensify lipid peroxidation, thereby augmenting oxidative stress within the placenta. Furthermore, offspring of mothers with obesity established by HFD exhibited elevated levels of triglycerides, cholesterol, and free fatty acids (FFA) in their blood circulation [67]. The elevation in maternal FFA levels intensifies insulin resistance by impairing glucose uptake and promoting hepatic gluconeogenesis [6]. GPX4 is situated within the cytoplasm and the mitochondrial intermembrane space, where it plays a crucial role in mitigating oxidative damage to mitochondria during cellular ferroptosis. GPX4 prompts the reduction of lipid peroxides to lipid alcohols through the oxidation of GSH [78]. Upon deactivation of GPX4, there is an accumulation of lipid ROS, which subsequently triggers the onset of ferroptosis [39]. Studies have found that exposure to elevated glucose levels significantly augmented oxidant production in trophoblasts, culminating in ferroptosis in human trophoblast cells; yet, the depletion of sirtuin 3 (SIRT3) inhibited ferroptosis through modulation of the AMPK-mammalian target of rapamycin (mTOR) signaling pathway and a concomitant promotion in GPX4 levels [81]. Another study found that elevated expression of circular RNA HIPK3 has the potential to facilitate ferroptosis in GDM by regulating the DNA methylation of GPX4 [82]. The intrinsic relationship between ferroptosis and GDM provides essential insights for the formulation of future intervention strategies. Further mechanistic studies are needed to understand the detrimental impact that ferroptosis can have on placental function under conditions of GDM (Table 1). Table 1Effects of oxidative stress, mitochondrial dysfunction, and ferroptosis on the placentaMechanismsOxidative stressMitochondrial dysfunctionFerroptosisPhysiological pregnancyModerate oxidative stress during pregnancy is necessary for proper placental development [42]The placental trophoblast cells, exhibits significant metabolic activity and necessitates energy supplied by mitochondria to maintain these vital functions [46]Maintaining iron homeostasis is crucial for supporting trophoblast function [32]Comparisons of the STBs and the CTBs in placentaSTBs possess cytochrome P450scc within their inner mitochondrial membrane, which is involved in superoxide production and rendering STBs more susceptible to ROS compared to CTBs [46]Compared to CTBs, STBs exhibit a reduced capacity for antioxidant activity, diminished mitochondrial respiration, and altered metabolic processes. These characteristics position them as the most sensitive region of the placenta in responding to fluctuations in oxygen levels [10]Human placental trophoblasts exhibit sensitivity to ferroptosis [83], with STBs demonstrating greater susceptibility to ferroptotic cell death compared to CTBs [84]Impaired functions of the placental trophoblastsExcessive ROS exacerbates trophoblast damage, especially disrupts the characteristics of EVTs, impairs their proliferation and invasion capabilities, and elevates the risk of GDM [36, 83]Mitochondrial dysfunction compromises the production of ATP and increases ROS levels, which in turn promotes serine phosphorylation of insulin receptor substrate 1, thereby disrupting insulin signaling in trophoblast cells [85]Ferroptosis, marked by intracellular lipid peroxidation and increased ROS production, disrupts trophoblast invasion through the enhancement of fatty acid oxidation [70]Characteristics of the pathological changesLocalized elevated oxidative stress levels induce apoptosis and degeneration, processes believed to induce to villous regression and the formation of placental membranes [86]Cellular mitochondrial dysfunction presents mitochondrial morphological abnormalities, a diminished number of cristae, reduction of mitochondrial membrane potential, and enhanced mitochondrial membrane permeability [32, 39]Hyperglycemia induces ferroptosis in trophoblast cells, defined by diminished glutathione levels, impaired iron transport [87] and disturbances in iron metabolism [86]Impacts on the structure of placentaOxidative stress promotes pathological angiogenesis, causing structural abnormalities in the placental vasculature [34]Ultrastructural analysis of mitochondria in STBs affected by GDM revealed evidence of mitochondrial swelling and destruction [46, 55]Trophoblastic ferroptosis is characterized by significant alterations in the trophoblast plasma membrane, including macro-blebbing and vesiculation [88]ATP adenosine triphosphate, CTBs cytotrophoblasts, EVTs extravillous trophoblasts, GDM gestational diabetes mellitus, P450scc cholesterol side-chain cleavage enzyme, ROS reactive oxygen species, STBs syncytiotrophoblasts Effects of oxidative stress, mitochondrial dysfunction, and ferroptosis on the placenta ATP adenosine triphosphate, CTBs cytotrophoblasts, EVTs extravillous trophoblasts, GDM gestational diabetes mellitus, P450scc cholesterol side-chain cleavage enzyme, ROS reactive oxygen species, STBs syncytiotrophoblasts Interaction of oxidative stress, mitochondrial dysfunction, and ferroptosis in GDM In GDM, oxidative stress, mitochondrial dysfunction, and ferroptosis may interact and influence each other (Fig. 4). Placental development necessitates a distinct oxidative stress milieu, and an imbalance in oxidative stress within the placenta can disrupt lipid metabolism, potentially facilitating the onset of ferroptosis [87]. Mitochondria are a major site of intracellular iron metabolism. Mitochondria regulate intracellular iron balance by modulating its uptake, storage, and release [89]. In cases of intracellular iron overload, mitochondria can sense and respond to this imbalance and mitigate the associated damage by modulating iron metabolism pathways. Interaction of oxidative stress, mitochondrial dysfunction, and ferroptosis. High glucose could induce an increase in production of ROS, leading to oxidative stress and mitochondrial dysfunction. The diminished levels of SLC7A11 and GSH eventuate a decrease in activity of GPX4, which in turn induces ferroptosis by promoting lipid peroxidation. GLUT: glucose transporter; GPX4: glutathione peroxidase 4; GSH: glutathione; PUFA-OH: polyunsaturated fatty acid-alcohol; PUFA-OOH: polyunsaturated fatty acid-hydroperoxide; ROS: reactive oxygen species; SLC7A11: solute carrier family 7 member 11. Created in BioRender.com Iron, a crucial element for electron transfer in the oxidative respiratory chain, plays a vital role in providing energy to both pregnant women and fetuses, while also facilitating the generation of free radicals. Elevated ROS production has been shown to promote lipid peroxidation and trigger ferroptosis [89]. Conversely, improving mitochondrial function could potentially help in resisting ferroptosis. Research has demonstrated that antioxidants or enzymes specifically targeting mitochondria could inhibit ferroptosis [90]. For instance, antioxidant enzymes like GPX4 and SOD2 play a crucial role in preventing ferroptosis [91, 92]. When an excess of free iron accumulates in mitochondria, it can lead to the impairment of mitochondrial function [77], insufficient cellular energy supply, and expedite the onset of ferroptosis. Damage to mtDNA serves as one of the early indicators of cell death. High glucose induces mitochondrial damage, ROS production, which is associated with the activation of the cGAS-STING signaling pathway [55]. The release of mtDNA and the subsequent activation of STING-mediated autophagic cell death might trigger the onset of ferroptosis [93]. The levels of PUFAs are regulated by mitochondrial fission and have a direct impact on the process of ferroptosis [94, 95]. Long-chain PUFAs, such as arachidonic acid (AA) and adrenic acid (AdA), exhibit a heightened susceptibility to lipid peroxidation due to their high degree of unsaturation [78, 96]. Elevated concentrations of long-chain fatty acids such as linoleic acid (LA) and α‐linolenic acid (ALA), identified through metabolomic methodologies, have the potential to serve as effective biomarkers for the prediction and diagnosis of GDM [97], although further research is required to substantiate this claim. Strategies of prevention and intervention for GDM GDM pregnant women exhibit elevated levels of oxidative stress, indicating that these markers may serve as potential biomarkers for the early diagnosis of GDM [42]. Oxidative stress has the potential to induce fetal malformations due to the underdeveloped nature of the fetal antioxidant system, rendering it particularly vulnerable to the deleterious effects of oxidative stress [24]. The effective management of GDM and the monitoring of placental health may contribute to the reduction of oxidative stress and its associated risks. Substantial evidence indicates that antioxidant-based therapy represents a promising strategy of improving pregnancy outcomes [33]. The sufficient intake of antioxidants could play a crucial role in maintaining glucose homeostasis [98]. The antioxidants contribute to the mitigation of oxidative stress by neutralizing free radicals, which may subsequently decrease the complications associated with GDM, including fetal overgrowth and placental dysfunction. During pregnancy, the reduction in biomarkers, specifically GPX3 and selenoprotein P (SELENOP), is associated with an increased risk of GDM [99]. These antioxidants are selenium-containing proteins that play crucial roles in mitigating oxidative stress in the placenta. Recent studies indicate a correlation between selenium deficiency and GDM [100], and reduced serum GPX3 activity constitutes a significant risk factor for the development of GDM [99]. Selenium supplementation was observed to enhance the endogenous antioxidant potential of trophoblasts, and help safeguard against tissue injury associated with ferroptosis [101], contributing to the prevention and treatment of GDM [100]. These results imply that antioxidant supplementation may be advantageous for pregnant women with an elevated risk of developing GDM [72]. Furthermore, the current study has demonstrated that engaging in regular moderate physical activity mitigates oxidative stress by enhancing the expressions of SOD and CAT enzymes in the placenta [85]. Incorporating whole berries and leafy vegetables into the diets of patients with GDM significantly enhances serum antioxidant capacity, thereby directly mitigating oxidative stress [102]. Omega-3 fatty acids have been demonstrated to significantly decrease MDA levels, reduce lipid storage in the placenta [27] and enhance total antioxidant capacity (T-AOC) in pregnant women with GDM. Additionally, the administration of vitamin D, vitamin E, and vitamin C has proven effective in reducing MDA levels, thereby indicating a reduction in lipid peroxidation. A reduced intake of vitamin C, specifically less than 70 mg per day, was significantly correlated with an elevated risk of developing GDM. Therefore, a study recommends a daily supplemental intake of 500–1000 mg of vitamin C to potentially improve diabetes outcomes [103]. However, further clinical trials are necessary to establish data for pregnant populations. Research utilizing obese mouse models has demonstrated that dietary supplementation with antioxidants results in a reduction of oxidative stress markers [104, 105]. The significance of natural or synthetic compounds like vitamin E has been extensively acknowledged for their role in alleviating oxidative stress and safeguarding placental health. Dietary antioxidants, like carotenoids, have been demonstrated to mitigate ROS and oxidative stress. It also influences transcription factors, such as NF-κB and NRF2, which play a crucial role in the development of insulin resistance and β-cell dysfunction [106]. The utilization of probiotics among pregnant women is on the rise and is generally considered safe and well-tolerated [107]. There is increasing evidence that the efficacy of probiotics in enhancing T-AOC and reducing MDA levels, underscoring their potential role in managing oxidative stress associated with GDM [22, 23]. Probiotics, such as Bifidobacterium and Lactobacillus, are microorganisms that confer health benefits to the host. Studies indicate that probiotics may enhance GSH levels, consequently mitigating inflammation and oxidative stress [39, 108]. Evidence shows that dendrobium mixture, a traditional Chinese medicinal formulation, could alleviate the level of MDA in the context of GDM, thereby suggesting its potential efficacy in mitigating lipid peroxidation [109]. Cryptotanshinone markedly decreased blood glucose levels, oxidative stress, and inflammation in the GDM mouse model, while concurrently enhancing insulin concentrations in both the placenta and blood [110]. A study revealed that estradiol supplementation could suppress high glucose-induced apoptosis in trophoblasts, mitigate oxidative stress, and reduce placental necrosis in mouse models of GDM [30]. Natural polyphenol antioxidant resveratrol showed favorable results on modulating oxidative stress. Resveratrol has been shown to exert embryo-protective effects, which are mediated through the reduction of oxidative stress and apoptosis in developing embryos [36]. In animal models of GDM, resveratrol supplementation has been found to protect against glucose intolerance, enhance insulin secretion, and mitigate insulin resistance induced by HFD. Furthermore, hepatic steatosis and insulin resistance were attenuated in the offspring of dams treated with resveratrol [111]. The encapsulation of resveratrol using chitosan represents a novel approach to reducing adverse effects while enhancing bioavailability [112]. Developing therapeutics aimed at placental mitochondria could enhance pregnancy outcomes [10]. Mitochondrial-targeted therapies are designed to maintain mitochondrial integrity, enhance oxidative function, and mitigate metabolic disturbances. Metformin is reported to promote mitophagy, the removal of damaged mitochondria, which improves mitochondrial health and boosts insulin sensitivity [113]. The antioxidant MitoQ, which is among the most extensively researched mitochondria-targeted synthetic antioxidants [46], could be transformed into its active ubiquinol form through the respiratory chain, serving as a potent antioxidant that averts lipid peroxidation and mitochondrial harm [114]. The application of MitoQ contributed to a reduction in placental MDA and decrease levels of lipid peroxidation [115]. MitoQ could be a promising target for future treatments aimed at enhancing pregnancy outcomes. Further research is warranted to investigate targeted therapies aimed at mitigating oxidative stress within the placenta, which could potentially improve outcomes in pregnancies affected by GDM. Conclusions The global prevalence of GDM has risen in recent years, emerging as a significant concern in the domain of women’s health. It is clearly recognized that the placenta is a functional interface of the maternal and fetal metabolisms. The placenta facilitates communication between the mother and her fetus through the transfer of metabolic substrates. The metabolic disturbances associated with GDM result in elevated levels of glucose and fatty acids within the maternal system, which may contribute to placental dysfunction. A growing body of evidence supports the pivotal role of placental oxidative stress, mitochondrial dysfunction, and ferroptosis in promoting the development of GDM. Here, we examined these pathophysiological mechanisms in GDM with a focus on the implications of the placenta. Treatment with antioxidants may benefit placental health and improve adverse pregnancy outcomes in GDM. Further mechanistic studies are needed to explore the therapeutic prospects of antioxidants’ treatment strategies. Acknowledgements We sincerely thank BioRender.com. Abbreviations 4-Hydroxynonenal 8-Iso-prostaglandin F2α 8-Hydroxy-2′-deoxyguanosine Arachidonic acid Adrenic acid Advanced glycation end-products α-Linolenic acid AMP-activated protein kinase α Adenosine triphosphate Body mass index Catalase Cyclic GMP-AMP synthase Cytotrophoblasts Dynamin-related protein 1 Disulfide-bond A oxidoreductase-like protein Extravillous trophoblasts Free fatty acids Gestational diabetes mellitus Glucose transporters Glutathione peroxidase Glutathione Glutathione-S-transferase High-fat diet Heme oxygenase-1 Janus kinase Linoleic acid Lipid peroxidation Mitogen-activated protein kinase Malondialdehyde Mitofusin 1/2 Mitochondrial DNA Mammalian target of rapamycin Nicotinamide adenine dinucleotide phosphate Nuclear factor-kappa B Nuclear factor erythroid 2-related factor 2 Optic atrophy 1 Peroxisome proliferator-activated receptor-γ coactivator-1α Polyunsaturated fatty acids Cholesterol side-chain cleavage enzyme Reactive oxygen species Selenoprotein P Serum ferritin Sulforaphane Sirtuin 3 Solute carrier family 7 member 11 Superoxide dismutase Signal transducers and activators of transcription 3 Syncytiotrophoblasts Stimulator of interferon genes Total antioxidant capacity Thiobarbituric acid reactive substances Mitochondrial transcription factor A Thioredoxin-interacting protein Xanthine oxidase Author contribution Xuan Zhou, Ling Feng, and Jianli Wu conceived and designed the research. Huiting Zhang, Lijie Wei, Zizhuo Wang, and Shenglan Zhu performed the literature search and data analysis. Xuan Zhou drafted the manuscript and prepared the figures. Jun Yu, Shaoshuai Wang, and Wencheng Ding edited and revised the manuscript. All authors read and approved the final manuscript. Funding This work was supported by the National Key Research and Development Program of China (Grant number: 2022YFC2704702) and the Tongji Hospital Scientific Research Fund Project (Grant number: 2024B27). Data availability No datasets were generated or analyzed during the current study. Declarations Ethics approval Not applicable. Consent to participate Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Ling Feng, Email: fltj007@163.com. Jianli Wu, Email: jlwu@tjh.tjmu.edu.cn. References Associated Data Data Availability Statement No datasets were generated or analyzed during the current study.